1Gozzo TO, Moyses AMB, Silva PR, et al. Nausea,vomiting and quality of life in women with breast cancer receiving chemotherapy[J]. Rev Gaticha Enferm, 2013, 34(3): 110-6.
2George D, Sasha M, Stephanie S, et al. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors[J]. Support Care Cancer, 2015, 23(1): 1-7.
3Hori K, Kobava N, Nagayama A, et al. Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network[J]. Support Care Cancer, 2014, 22(4): 969-77.
4NCCN Clinical Practice Guidelines in Oncology:Antiemesis. Version l[EB/OL].2014.[2014 02 25]. http://www.nccn.org/ professionals/physician_gls/pdf/antiemesis.pdf.
5Cello L, Denaro A, Agustoni F, et al. Palonosetron plus l-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial[J]. J Support Oncol, 2012, 10(2): 65-71.
6Ingersoll GL,Wasilewski A, Hailer M, et al. Effect of concord grape juice on chemotherapy-induced nausea and vomiting: results of a pilot study[J]. Oncol Nurs Forum, 2010, 37(2): 213-21.
7Pacetti U, Veltri E, Fattoruso SI, et al. Single-dose Palonosetron and Dose-reduced Regimen of Dexamethasone in Preventing Nausea and Vomiting by Anthracycline-including Chemotherapy in Patients with Early Breast Cancer[J]. Anticancer Res, 2013, 33(4): 1721-4.
